About this episode
Richard Waines is an Investor at DCVC Bio.
DCVC Bio invests in early-stage, deep-tech life science companies that are leveraging computational approaches, including AI and automation, to transform existing technologies and accelerate the development of new ones.
Chapters/Takeaways
03:19 → Journey into Biotech Investing
11:53 → DCVC Bio's Focus and Investment Strategy
16:19 → Exploring Platform Therapeutics in Biotech
20:15 → Nuances of Biotech Investing vs. Other Industries
23:11 → Managing Science Risk in Biotech Investments
27:58 → Key Personnel Changes During Company Growth
30:24 → Geographical Considerations in Biotech Investments
34:30 → The Passion for Science vs. Business in Biotech
36:08 → The Role of an Associate in Venture Capital
41:17 → The Impact of AI on Biotech Investments
Get every episode summarized
Each time The Hard Part with Evan McCann publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Hard Part with Evan McCann
Alison Kaizer and Andrew D'Souza
The Hard Part with Evan McCann
Max Cunningham from Sesh
The Hard Part with Evan McCann
Ian MacKinnon from Stingray Security
The Hard Part with Evan McCann
Robert Farlow from Plato
The Hard Part with Evan McCann